| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Sep, 2024 | Jun, 2024 | Sep, 2025 |
| Sales | 392 | 0 | 642 | 776 | 0 |
| Sales Growth | unch | -100.00% | -17.26% | unch | unch |
| Net Income | -14,775 | -293 | -16,213 | -1,443 | -2 |
| Net Income Growth | -4,941.74% | +98.19% | -1,023.58% | -65,782.57% | unch |
Tempramed Technologies Ltd.
(VIVI.CN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TempraMed Technologies Ltd develops patent-protected solutions for managing and protecting temperature-sensitive medications. Its product range includes VIVI Cap for insulin pens and VIVI Epi for epinephrine injectors, which are distributed through pharmacy and retail networks globally. TempraMed generates the majority of its revenue from the sales of these devices, serving patients, healthcare providers, and pharmacy systems through operations in Southeast Asia, Europe, and Central America. The company enhances its reach by forming partnerships in the healthcare sector to broaden its access and drive usage in various geographic markets.
Fiscal Year End Date: 12/31